ADRA2A and SLC30A8 have not been studied for an association with CRC, but the functional changes that have been reported followed by mutations (in ADRA2A, modified insulin release by adrenergic suppression, and in SLC30A8, altered storage and maturation of insulin in beta cells [40, 56]) support our findings of increased CRC risk in relation to these variants. The gene discussed is ADRA2A; the disease is colorectal carcinoma.